Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207400 · ClinicalTrials.gov registry record · Phase 2
To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT02207400: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT02207400 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 246 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207400, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
This study will compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Salus Research, Inc. Participants will be recruited from their database and by use of an external recruitment agency
Primary Outcome
The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
Interventions
- DRUG Sodium fluoride
- DRUG Sodium bicarbonate and sodium fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2014-08-25 |
| Est. Completion | 2015-04-30 |
| Phase | Phase 2 |
What the finished NCT02207400 record still lists
NCT02207400 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% higher).
The record links to 0 conditions, and to 2 interventions - of which Sodium fluoride is the first listed.
NCT02207400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02207400 about?
NCT02207400 is a clinical study titled "To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms". This study will compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Salus Research, Inc. Participants will be recruited f...
What is the current status of trial NCT02207400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2014-08-25. Estimated completion is 2015-04-30.
What interventions are being tested in trial NCT02207400?
The interventions under investigation include: Sodium fluoride (DRUG), Sodium bicarbonate and sodium fluoride (DRUG).
Who is sponsoring clinical trial NCT02207400?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02207400's enrollment target sits among peer trials
246 234th of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI